LLPC Associated studies

Open studies

Short name	Terzo
Study title	A multicentre open-label Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (TERZO)
Status	Open in ErasmusMC, LUMC en Amsterdam UMC
Medication	Duvelisib vs investigator’s choice (Gemcitabine of Bendamustine)
Population	Relapsed/refractory nodaal T-cel lymfoom met T follicular helper (TFH) fenotype na ≥1 eerdere lijn therapie
Study docs	In en exclusiecriteria

Short name	GOLSEEK-4
Study title	A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma
Status	open in AUMC, UMCU en UMCG
Population	Recurrent follicular lymphoma after at least one prior line of treatment with an anti-CD20 agent and an alkylating agent (e.g., cyclophosphamide, bendamustine). Note: there must be no evidence of prior transformation.
Study docs	In- en exclusiecriteria

Short name	CARMAN
Study title	Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
Status	open in Erasmus MC (Doorduijn) Open in UMCG (v Meerten) and Amsterdam UMC (Kersten) soon.
Population	previously untreated MCL, high risk. At least one High risk MCL feature, defined as I. MIPI-c high intermediate (HI) or high (H) risk (i.e. high-risk MIPI irrespective of Ki-67 or intermediate risk MIPI and Ki-67>=30% (Ki-67 based on local pathology) and/or II. TP53 deletion and /or mutation and/or TP53 overexpression by immunohistochemistry (> 50% of lymphoma cells), sequencing (mutations and deletions) or FISH
Study docs	In- en exclusiecriteria

Short name	Athena-1 (Regeneron)
Study title	A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 X anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
Status	Open in Erasmus MC and Amsterdam UMC
Medication	Odronextamab combined with REGN5837
Population	Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (DLBCL) after two lines including CAR T-cell therapy
Study docs	In and exclusion criteria

Short name	CA1231000
Study title	A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination with Anti-lymphoma Agents in Participants with Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Status	Open in MUMC (marjolein.vander.poel@mumc.nl) and in UMCG (m.nijland@umcg.nl)
Medication	BMS-986458; BCl6 degrader
Population	relapsed/refractory DLBCL and FL
study docs	In- and exclusion criteria

Short name	KT-US-499-0150
Study title	A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Status	Open in Amsterdam UMC, location VUMC (m.j.kersten@amsterdamumc.nl, ilse.kuipers@amsterdamumc.nl, trialbureaulymfoid@amsterdamumc.nl)
Medication	KITE-363 & KITE-753; Autologous anti-CD19/CD20 chimeric antigen receptor [CAR] T-cell product
Population	Relapsed and/or Refractory B-cell Lymphoma
Study info	Study information
Study docs	In- and exclusion criteria

Short name	NX-5948-301
Study title	A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Status	open in ErasmusMC (j.doorduijn@erasmusmc.nl) and RadboudUMC (W. Stevens), UMCU (Utrecht) (A. Pulles), UMCG (Groningen) (M.Nijland)
Medication	BTK-degrader (oral)
Population	R/R CLL/SLL with CNS involvement
Study Docs	In- en exclusiecriteria Advertentie text (approved by EC)

Atalanta-1 (CP0201-NHL)

ZUMA 23

CD19/CD20 biCAR

BYON4228

OLYMPIA-4

Magnaz

M22-132

GCT3014-01

R/R CLL (GCT3013-03)

DALY 2-EU

EPCORE NHL-2

ZUMA-2 cohort

GEN3009

Valentine study

Lym1002

EDO-S101-1001

TRANSCEND WORLD (Celgene JCAR017-BCM-001)

CDK9

ACT15320

BELINDA (CCTL019H2301)

TRANSFORM (Celgene JCAR017-BCM-003

Harbour